Pulmonary sarcoidosis is a lung disease characterized by granulomas — tiny clumps of immune cells that form in response to inflammation. It’s the most inflammatory of the interstitial lung diseases (ILDs), a family of conditions that all involve some level of inflammation and fibrosis, or scarring, of the lungs. In the U.S., pulmonary sarcoidosis affects around 200,000 patients. The cause is unknown, and no new treatments have been introduced in the past 70 years.

In a paper published in Science Translational Medicineon March 12, 2025, scientists at Scripps Research and aTyr Pharma characterized a protein, HARS^WHEP, that can soothe the inflammation associated with sarcoidosis by regulating white blood cells. Reducing inflammation slows the disease’s progression and results in less scarring. A phase 1b/2a clinical trial of efzofitimod, a therapeutic form of HARS^WHEP, showed promising results.

“Taken together, these results validate a new way to approach immune regulation in chronic lung disease,” says Paul Schimmel, professor of molecular medicine and chemistry at Scripps Research and the study’s senior author.

The drug’s power lies in its gentle nature. “It’s not a hammer; it’s not overly suppressing the immune system. It’s just nudging the immune system in a certain way,” explains Leslie A. Nangle, Vice President of Research at aTyr Pharma and the paper’s first author. “And if you can quiet the inflammation, you can stop the cycle of ongoing fibrosis.”

HARS^WHEP is part of an ancient class of proteins known as aminoacyl-tRNA synthetases (aaRSs). Typically, aaRSs play a key role in protein synthesis. “They’re in every cell in your body. They’re in every organism on the planet,” Nangle says. Over time, new versions known as splice variants have emerged that bind to receptors on the outsides of cells and initiate different events throughout the body.

One such variant, HARS^WHEP, entered the picture about 525 million years ago. Nangle and Schimmel screened more than 4,500 receptors and were surprised to find that HARS^WHEP will bind only to the receptor neuropilin-2 (NRP2). This receptor is known for its role in development of the lymphatic system — the circulatory system through which immune cells travel — not immune function. But the researchers found that when small, circulating white blood cells known as monocytes enter a tissue in response to inflammation and develop into larger, more specialized white blood cells known as macrophages, those cells start to express high levels of NRP2.

“We had a protein with an unknown function. We had a receptor that was doing something on immune cells that had never been characterized. So we had a couple things we had to match up,” Nangle says.

The team found that HARS^WHEP binding to NRP2 physically transforms the macrophage. “It’s creating a new type of macrophage that is less inflammatory and actually helps to resolve inflammation,” Nangle explains.

To characterize HARS^WHEP‘s mechanism of action, the team administered the protein in mice and rats and found that it reduced lung inflammation and the progression of fibrosis.

In separately published clinical trial data, the team saw a positive impact on patients who were treated with efzofitimod while tapering off of oral corticosteroids. Long-term steroid treatment, currently the first-line option, is associated with significant weight gain and organ damage, and the immunosuppressive effects leave patients vulnerable to infection.

The team also characterized patients’ circulating immune cells before and after efzofitimod treatment. They saw that it reduced key indicators of the inflammation that drives sarcoidosis, such as the concentration of macrophages and other inflammatory immune cells.

While they’re exploring sarcoidosis first, efzofitimod is a potential treatment for many interstitial lung diseases, Nangle explains. The aTyr team plans to explore treating other ILDs and is running a clinical trial now for scleroderma-related ILD.

The work highlights macrophages as a possible target for treating ILDs, and the promise of HARS^WHEP could foretell other aaRSs’ therapeutic potential.

Nangle describes this work as moving “from concept to clinic.” Schimmel has worked on aaRSs throughout his tenure at Scripps Research. aTyr Pharma spun out of Schimmel’s lab; his former graduate student Nangle was the company’s first employee upon opening their labs in 2006.

“Original work that happened at Scripps gave rise to the idea that this could be a new class of therapeutic molecules, Nangle says. “We have now moved it all the way to clinical development. It’s a proof of concept for this whole class of molecules and the work Paul has done.”

In addition to Nangle and Schimmel, authors of the study “A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis” include Zhiwen Xu, David Siefker, Christoph Burkart, Yeeting E. Chong, Clara Polizzi, Lauren Guy, Lisa Eide, Sofia Klopp-Savino, Michaela Ferrer, Kaitlyn Rauch, Annie Wang, Kristina Hamel, Steve Crampton, Suzanne Paz, Kyle P. Chiang, Minh-Ha Do, Luke Burman, Darin Lee, Kathleen Ogilvie, David King, and Ryan A. Adams of aTyr Pharma and Liting Zhai, Yanyan Geng, Yao Tong, and Mingjie Zhang of IAS HKUST-Scripps R&D Laboratory at the Hong Kong University of Science and Technology.

This work was supported by funding from aTyr Pharma and the National Foundation for Cancer Research

date:2025-04-07 23:50:00

A Gentle Approach Offers New Hope for Inflammatory Lung Diseases

Table of Contents

A Gentle Approach Offers New Hope for Inflammatory Lung Diseases

Inflammatory lung diseases encompass a range of conditions that affect the airways and lung tissue, causing inflammation and often leading to breathing difficulties. Conditions like asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and interstitial lung diseases (ILDs) can substantially impact a person’s quality of life. While conventional treatments like bronchodilators, corticosteroids, and oxygen therapy play a crucial role, an emerging “gentle approach” focusing on personalized care, lifestyle modifications, and innovative therapies is offering new hope for improved outcomes.

Understanding Inflammatory Lung Diseases

Before diving into the gentle approach,it’s essential to understand the complexities of inflammatory lung diseases. These conditions are characterized by chronic inflammation in the lungs, which can damage the airways and air sacs (alveoli). This damage can obstruct airflow, making it difficult to breathe, and impair the lungs’ ability to exchange oxygen and carbon dioxide. Understanding the specific type of lung disease and its underlying cause is crucial for developing an effective treatment plan.

Common Inflammatory Lung Diseases:

Asthma: A chronic inflammatory disease that narrows the airways, causing wheezing, coughing, and shortness of breath.
COPD: Frequently enough caused by smoking, COPD includes emphysema and chronic bronchitis, leading to irreversible airflow obstruction.
bronchiectasis: Permanent widening and thickening of the airways, causing mucus buildup and increasing the risk of infections.
Interstitial Lung Diseases (ILDs): A group of disorders that cause scarring (fibrosis) in the lungs, making it difficult to breathe.Examples include idiopathic pulmonary fibrosis (IPF) and sarcoidosis.

The Core Principles of a Gentle Approach

the “gentle approach” isn’t about dismissing conventional medicine; rather, it complements it with strategies that prioritize minimizing side effects, empowering patients, and promoting overall well-being. It’s about addressing the disease holistically, focusing on the individual’s specific needs and circumstances.

Key Components of the Gentle Approach:

Personalized Medicine: Tailoring treatment plans to individual genetic profiles, disease severity, and lifestyle factors.
Minimizing Medication Side Effects: Exploring alternative delivery methods, lower dosages, and complementary therapies to reduce adverse reactions.
Lifestyle Modifications: Emphasizing smoking cessation, pulmonary rehabilitation, proper nutrition, and stress management techniques.
Integrative Therapies: Incorporating evidence-based complementary therapies, such as yoga, acupuncture, and mindfulness, to improve lung function and quality of life.
Patient Empowerment: Educating patients about their condition and treatment options, enabling them to actively participate in their care.

Personalized Medicine: Tailoring Treatment to the Individual

One of the cornerstones of the gentle approach is personalized medicine. Recognizing that each patient is unique, this strategy involves analyzing individual factors, such as genetic predispositions, disease stage, and response to previous treatments, to create a customized treatment plan.

Pharmacogenomics: The Role of Genes

Pharmacogenomics plays a vital role in personalized medicine for inflammatory lung diseases. By analyzing an individual’s genes, doctors can predict how they will respond to specific medications. This can help avoid adverse drug reactions and optimize treatment efficacy. For example, certain genetic variations can affect how a person metabolizes corticosteroids, influencing the dosage needed to achieve the desired effect.

Phenotyping: Understanding Disease Subtypes

Inflammatory lung diseases often present with varying phenotypes, or observable characteristics. Phenotyping involves identifying distinct subgroups within a disease population based on factors like disease severity, inflammation patterns, and response to therapy. This allows doctors to target specific treatment strategies to each subgroup, improving outcomes.

Minimizing Medication Side Effects

Many medications used to treat inflammatory lung diseases, such as corticosteroids and bronchodilators, can cause side effects. The gentle approach focuses on minimizing these side effects thru various strategies.

Alternative Delivery Methods

Using inhaled medications rather than oral or intravenous forms can reduce systemic exposure to the drug and minimize side effects. For example, inhaled corticosteroids are often preferred over oral corticosteroids for asthma because they deliver the medication directly to the lungs, reducing the risk of systemic side effects like weight gain, osteoporosis, and mood changes.

Lower Dosages and Gradual Tapering

Using the lowest effective dose of medication and gradually tapering off the dosage when possible can help minimize side effects while maintaining disease control. this approach requires careful monitoring and collaboration between the patient and healthcare provider.

Complementary Therapies

Complementary therapies, such as herbal remedies and nutritional supplements, may help reduce the need for conventional medications and minimize their side effects. However, it’s crucial to discuss these therapies with a healthcare provider to ensure they are safe and effective.

Lifestyle Modifications: Empowering patients to Take Control

Lifestyle modifications are an integral part of the gentle approach, empowering patients to actively participate in their care and improve their overall health. These modifications include:

Smoking Cessation

For individuals with COPD and other smoking-related lung diseases, smoking cessation is the single most crucial intervention. Quitting smoking can slow the progression of the disease, improve lung function, and reduce the risk of exacerbations. Support groups, counseling, and nicotine replacement therapy can help individuals successfully quit smoking.

Pulmonary rehabilitation

Pulmonary rehabilitation is a comprehensive programme designed to improve lung function, exercise tolerance, and quality of life for individuals with chronic lung diseases. It typically includes exercise training,breathing techniques,education about lung disease management,and psychosocial support.

nutrition and Diet

Proper nutrition plays a vital role in maintaining lung health. A balanced diet rich in fruits, vegetables, and lean protein can provide the nutrients needed to support lung function and reduce inflammation. Adequate hydration is also essential for keeping mucus thin and easier to clear. For some lung diseases such as Sarcoidosis, limiting Calcium and Vitamin D intake is importent as well.

Stress Management

Stress can exacerbate symptoms of inflammatory lung diseases. Stress management techniques, such as yoga, meditation, and deep breathing exercises, can help reduce stress and improve overall well-being.

Integrative Therapies: Incorporating Complementary Approaches

Integrative therapies combine conventional medicine with evidence-based complementary approaches to promote holistic healing and improve quality of life. Some commonly used integrative therapies for inflammatory lung diseases include:

yoga

Yoga involves physical postures, breathing exercises, and meditation, which can improve lung function, reduce stress, and enhance overall well-being. Specific breathing techniques, such as diaphragmatic breathing and pursed-lip breathing, can help improve lung capacity and reduce shortness of breath.

Potential Benefits of Yoga:

increased lung capacity
Improved breathing efficiency
Reduced stress and anxiety
Enhanced quality of life

Acupuncture

Acupuncture involves inserting thin needles into specific points on the body to stimulate energy flow and promote healing. Some studies suggest that acupuncture may help improve lung function and reduce inflammation in individuals with asthma and COPD.

Mindfulness

Mindfulness practices, such as meditation and mindful breathing, can help reduce stress, improve emotional regulation, and enhance overall well-being.Mindfulness can also help individuals cope with the challenges of living with a chronic lung disease.

Patient Empowerment: Fostering Active Participation

The gentle approach emphasizes patient empowerment,recognizing that informed and engaged patients are more likely to adhere to their treatment plans and achieve better outcomes. This involves:

Education and Details

Providing patients with clear and accurate information about their condition, treatment options, and self-management strategies. This empowers them to make informed decisions about their care.

Shared Decision-Making

involving patients in the decision-making process, considering their preferences, values, and goals. This fosters a sense of partnership and collaboration between the patient and healthcare provider.

Support Groups

Encouraging patients to participate in support groups, where they can connect with others who have similar experiences, share information, and offer emotional support.

Emerging Therapies and Research

The field of inflammatory lung disease treatment is constantly evolving, with new therapies and research emerging. Some promising areas of investigation include:

Biologic Therapies

Biologic therapies target specific molecules involved in the inflammatory process, such as cytokines and chemokines. These therapies can help reduce inflammation and improve lung function in individuals with certain types of inflammatory lung diseases, such as severe asthma.

Bronchial Thermoplasty

Bronchial thermoplasty is a procedure that uses heat to reduce the amount of smooth muscle in the airways, reducing airway constriction and improving breathing in individuals with severe asthma.

Regenerative Medicine

Regenerative medicine aims to repair or replace damaged lung tissue using stem cells or other regenerative therapies. This approach holds promise for treating irreversible lung damage caused by conditions like COPD and IPF.

First-Hand experience: A Patient’s Journey

Sarah, a 52-year-old woman, was diagnosed with mild COPD after experiencing persistent shortness of breath and chronic cough. Initially, she relied solely on her prescribed inhalers for relief, but found that her symptoms persisted, and she didn’t like the side effects of the inhaler medication. She began to explore the gentle approach.

Sarah’s Journey Included:

Pulmonary Rehabilitation: She joined a local pulmonary rehabilitation program, where she learned breathing exercises, strength training, and techniques for managing her symptoms.
Diet and Nutrition: After consulting with a nutritionist, Sarah learned about anti-inflammatory foods and how to create meal plans that support her immune system, reduce airway inflammation to improve healing and reduce disease complications .
Mind Body Healing Practices: Sarah started practicing mindfulness and yoga. Soon, she noticed that her lung function seemed better and her medications were working better.

The conversion that Sarah experienced was incredible. As her knowledge of how to implement a few lifestyle change processes, she noted that this greatly reduced COPD symptoms. Sarah reports that with the holistic approach,medications,and her strong support team,she is now able to continue her favorite hobbies and activities.

Case study: Managing Asthma with Integrative Therapies

A 35-year-old male patient, John, had severe asthma that was poorly controlled despite high doses of inhaled corticosteroids and long-acting beta-agonists. He experienced frequent exacerbations requiring emergency room visits. Frustrated with his lack of progress, John sought an integrative approach.

Intervention:

Acupuncture: John began receiving weekly acupuncture treatments,focusing on points known to improve lung function and reduce inflammation.
herbal Medicine: A qualified herbalist prescribed a customized herbal formula to address his specific asthma triggers and symptoms.
Stress Management: John practiced daily meditation and attended a mindfulness-based stress reduction (MBSR) program.

Outcome:

After three months, John experienced a significant reduction in asthma symptoms and exacerbations. he was able to reduce his dependence on rescue inhalers and lower the dose of his inhaled corticosteroids. his quality of life improved significantly.

Benefits and Practical tips for Implementing the Gentle approach

Implementing a gentle approach offers numerous benefits,including:

Improved symptom control
Reduced medication side effects
Enhanced quality of life
Empowered patients
Holistic healing

Practical Tips:

Consult with a healthcare provider experienced in integrative medicine.
Develop a personalized treatment plan that addresses your specific needs and goals.
Prioritize lifestyle modifications, such as smoking cessation, pulmonary rehabilitation, and proper nutrition.
Explore evidence-based complementary therapies, such as yoga, acupuncture, and mindfulness.
Actively participate in your care and communicate openly with your healthcare team.

Insurance Coverage and Accessibility

One of the challenges of implementing the gentle approach is insurance coverage for complementary and integrative therapies. While some insurance plans may cover acupuncture, chiropractic care, and pulmonary rehabilitation, others may not. It’s important to check with your insurance provider to determine what services are covered.

Accessibility can also be a barrier,particularly in rural areas where there may be limited access to integrative healthcare providers. Telemedicine and online resources can help bridge this gap, providing access to information and support for individuals who live in remote areas.

Building a Supportive Community

Living with an inflammatory lung disease can be isolating and challenging. Building a supportive community of family,friends,and healthcare professionals is essential for maintaining emotional well-being and improving outcomes. Support groups, online forums, and social media groups can provide valuable resources for connecting with others who have similar experiences.

Patient Education and Awareness Campaigns

Raising awareness about inflammatory lung diseases and the benefits of the gentle approach is crucial. Patient education campaigns can help inform individuals about the importance of early diagnosis, lifestyle modifications, and integrative therapies. These campaigns can also help reduce stigma and promote access to care.

The Future of Lung Disease Management: A Shift Towards Gentler Approaches

The future of lung disease management is likely to see a greater emphasis on gentle approaches that prioritize personalized care, lifestyle modifications, and integrative therapies.As research continues to uncover the complexities of inflammatory lung diseases, new and innovative treatments will emerge that offer improved outcomes with fewer side effects.

Key Trends in Lung Disease Management:

Trend	Description
Precision Medicine	Tailoring treatment plans based on individual genetic and molecular profiling.
Digital health	Using wearable sensors and mobile apps to monitor lung function and provide remote patient monitoring.
Artificial Intelligence	Utilizing AI to analyze medical images and predict disease progression.
Patient-Centered Care	Empowering patients to actively participate in their care and make informed decisions.

A gentle approach offers new hope for inflammatory lung diseases